<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02715713</url>
  </required_header>
  <id_info>
    <org_study_id>L16-059</org_study_id>
    <nct_id>NCT02715713</nct_id>
  </id_info>
  <brief_title>Autonomic Manifestations of Testosterone Deficiency in Men</brief_title>
  <official_title>Autonomic Manifestations of Testosterone Deficiency in Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this pilot study is to investigate the association between testosterone&#xD;
      deficiency and the presence of abnormalities in the function of the autonomic nervous system.&#xD;
      If such association exists, then we will investigate the effect of testosterone replacement&#xD;
      therapy on correcting these abnormalities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will recruit 40 men between the ages of 40 to 80-years-old with low&#xD;
      testosterone. Participants will be selected among those males referred to the Texas Tech&#xD;
      University Health Sciences Center's (TTUHSC's) Internal Medicine Endocrinology Division&#xD;
      outpatient clinic for the study and management of testosterone deficiency and to the TTUHSC&#xD;
      Urology Department for diagnosis and management of prostate cancer that will result in&#xD;
      testosterone deficiency due to surgical or pharmacological castration.&#xD;
&#xD;
      After recruitment, patients will have an initial standard clinical visit where aspects such&#xD;
      as fatigue and anxiety will be investigated, followed by a full battery of autonomic testing&#xD;
      (tilt table, heart rate response to deep breathing, Valsalva, and the Quantitative Sudomotor&#xD;
      Axon Reflex Test (QSART).&#xD;
&#xD;
      Those patients with an initial diagnosis of testosterone deficiency will be initiated on&#xD;
      testosterone replacement (intramuscular or skin routes) as standard of care, followed by a&#xD;
      second visit in three (3) months--after normalization of serum testosterone levels--to&#xD;
      evaluate changes in anxiety and fatigue level, and to repeat the cardiovascular autonomic&#xD;
      function test.&#xD;
&#xD;
      Those patients with primary diagnosis of prostate cancer and normal serum testosterone levels&#xD;
      will be evaluated a second time after confirmation of low testosterone, as described above.&#xD;
      Standard questionnaires will be used to evaluate fatigue and anxiety. The autonomic testing&#xD;
      of the heart will include tilt table (tilt the patient 70 degree by special designed table)&#xD;
      and heart rate response to deep breathing, and Valsalva maneuver. Descriptive statistics will&#xD;
      be compared between before and after treatment using different statistical methods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Principal Investigator left the institution in August, 2016;&#xD;
  </why_stopped>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with testosterone deficiency who will have abnormal autonomic function test (abnormal heart rate response to deep breathing, abnormal Valsalva ratio, and abnormal tilt table i.e. orthostatic hypotension).</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with testosterone deficiency and abnormal autonomic function test who will have such abnormalities corrected if they receive testosterone replacement therapy as part of standard of care.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Autonomic Neuropathy</condition>
  <condition>Male Hypogonadism</condition>
  <arm_group>
    <arm_group_label>testosterone deficiency group</arm_group_label>
    <description>Men between the ages of 40 to 80-years-old with testosterone deficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prostate cancer group</arm_group_label>
    <description>Men between the ages of 40 to 80-years-old with prostate cancer that will result in testosterone deficiency due to surgical or pharmacological castration.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Two groups will be recruited with 20 men in each group:&#xD;
&#xD;
        Group 1 will include 20 men between the ages of 40 to 80-years-old with symptoms and&#xD;
        biochemical parameters of low testosterone.&#xD;
&#xD;
        Group 2 will include 20 men between the ages of 40 to 80-years-old with prostate cancer and&#xD;
        normal serum testosterone that will be treated with surgical or pharmacological castration,&#xD;
        as following standard of care at Urology Division, resulting in testosterone deficiency.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for first group:&#xD;
&#xD;
          1. Patients with testosterone deficiency (total testosterone&lt; 277 ng/dL [9.6 nmol/L])&#xD;
             measured between 7-10 am, and with one or more symptoms and signs suggestive of&#xD;
             androgen deficiency as mainly determined by history.&#xD;
&#xD;
               -  Reduced sexual desire (libido)&#xD;
&#xD;
               -  Decreased spontaneous erections&#xD;
&#xD;
               -  Breast discomfort, gynecomastia&#xD;
&#xD;
               -  Loss of body (axillary and pubic) hair - reduced shaving&#xD;
&#xD;
               -  Very small (&lt;5ml) or shrinking testes&#xD;
&#xD;
               -  Height loss&#xD;
&#xD;
               -  Low trauma fracture&#xD;
&#xD;
               -  Low bone mineral density&#xD;
&#xD;
               -  Hot flushes&#xD;
&#xD;
               -  Sweats&#xD;
&#xD;
               -  Decreased energy&#xD;
&#xD;
               -  Decreased motivation&#xD;
&#xD;
               -  Decreased initiative&#xD;
&#xD;
               -  Decreased self confidence&#xD;
&#xD;
               -  Feeling sad or blue&#xD;
&#xD;
               -  Depressed mood&#xD;
&#xD;
               -  Dysthymia&#xD;
&#xD;
               -  Poor concentration&#xD;
&#xD;
               -  Poor memory&#xD;
&#xD;
               -  Sleep disturbance&#xD;
&#xD;
               -  Increased sleepiness&#xD;
&#xD;
          2. Age 40 to 80 years&#xD;
&#xD;
        Inclusion Criteria for second group:&#xD;
&#xD;
          1. Patients who underwent chemical or surgical castration for prostatic cancer who are&#xD;
             going to receive androgen deprivation therapy.&#xD;
&#xD;
          2. Age 40 to 80 years&#xD;
&#xD;
        Exclusion Criteria (both groups):&#xD;
&#xD;
        1. Patients with history or current diagnosis of:&#xD;
&#xD;
          -  Atrial fibrillation.&#xD;
&#xD;
          -  Cardiac arrythmia&#xD;
&#xD;
          -  Pacemaker placement.&#xD;
&#xD;
          -  Myocardial infarction &lt; 3 months&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus with hemoglobin A1c &gt; 8.5% in the last 6 months.&#xD;
&#xD;
          -  Diabetes mellitus with autonomic neuropathy&#xD;
&#xD;
          -  Breast cancer&#xD;
&#xD;
          -  Heart failure with left ventricular ejection fraction below 35%.&#xD;
&#xD;
          -  Severe sleep apnea.&#xD;
&#xD;
          -  Recent eye surgery (&lt; 3 months)&#xD;
&#xD;
          -  Recent ischemic stroke (&lt; 3 months)&#xD;
&#xD;
          -  History of retinal detachment.&#xD;
&#xD;
          -  History of brain aneurysm.&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease (COPD) on oxygen therapy.&#xD;
&#xD;
          -  Intraocular hemorrhage and lens dislocation.&#xD;
&#xD;
          -  Glaucoma.&#xD;
&#xD;
          -  Thyroid disease.&#xD;
&#xD;
          -  Not literate in English&#xD;
&#xD;
        Exclusion Criteria for patient who will receive testosterone treatment&#xD;
&#xD;
          -  Metastatic prostate cancer&#xD;
&#xD;
          -  Prostate-specific antigen (PSA) concentration &gt;4.0 mcg/L,&#xD;
&#xD;
          -  Prostate-specific antigen (PSA) &gt;3.0 mcg/L in high-risk men (African-Americans or men&#xD;
             with first-degree relatives with prostate cancer). (Measured at clinic visit 1)&#xD;
&#xD;
          -  Polycythemia (hemoglobin level &gt;18 g/dL, hematocrit &gt; 52%) (measured at clinic visit&#xD;
             1)&#xD;
&#xD;
          -  Severe acne.&#xD;
&#xD;
          -  History of venous or arterial thrombosis.&#xD;
&#xD;
          -  Persons not literate in English&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M Eldokla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Tech Universty Health Science Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79430</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>March 17, 2016</study_first_submitted>
  <study_first_submitted_qc>March 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>October 14, 2016</last_update_submitted>
  <last_update_submitted_qc>October 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autonomic neuropathy, Testosterone Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

